A pivotal Phase 3 clinical trial testing pridopidine, an experimental oral therapy being developed by Prilenia Therapeutics and Ferrer, in people with early, rapidly progressive amyotrophic lateral sclerosis (ALS) has enrolled its first participant. PREVAiLS (NCT07322003), which was cleared late last year by the…